Skip to main content

Remote Job Finders (RJF)

Stealth Cuts 30% of Workforce Following FDA Rejection, Still Eyes Barth Approval

Although the FDA has rejected Stealth’s new drug application for Barth syndrome candidate elamipretide, the agency identified a potential accelerated approval pathway. The company has pared down its staff to conserve resources to fund a potential resubmission.

Sounding Off: Political Climate, Job Market Have Some Eyeing Biopharma Work Abroad

Nearly a third of employed and almost half of unemployed BioSpace survey respondents are seriously considering leaving the U.S. to find biotech and pharma jobs. Concerns about how the political climate is affecting biopharma are a key driver for many.
Scroll to top